Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature
L. Pi(University of Ottawa), Grace Christou(University of Ottawa), Harold Atkins(University of Ottawa), William L. Stanford(University of Ottawa), AJ Fulcher(University of Ottawa), Tim Ramsay(University of Ottawa), Caryn Y. Ito(University of Ottawa), Shorr(Ottawa Hospital), Jasjit Rooprai(University of Ottawa), David Allan(University of Ottawa), Mitchell Sabloff(University of Ottawa), Christopher Bredeson
Cited by 24
Related Papers
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|598
A FLUORINATED GLUCOSE ANALOG, 2-FLUORO-2-DEOXY-D-GLUCOSE (F-18)
|Journal of Computer Assisted Tomography|1980|503
Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research
|Biology of Blood and Marrow Transplantation|2014|442